Overview

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

The routine administration of 75 mg of intravenous aminophylline in patients with severe chronic kidney disease undergoing a nuclear stress test with regadenoson (Lexiscan®) can reduce or eliminate the incidence of diarrhea and other side effects related to regadenoson.

Phase:

Phase 4

Details

Lead Sponsor:

Rush University Medical Center

Collaborator:

John H. Stroger Hospital

Treatments:

Aminophylline
Regadenoson